Pfizer Inc. $PFE Stake Lifted by Sax Wealth Advisors LLC

Sax Wealth Advisors LLC increased its stake in Pfizer Inc. (NYSE:PFE) by 71.4% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 19,365 shares of the biopharmaceutical company’s stock after acquiring an additional 8,066 shares during the period. Sax Wealth Advisors LLC’s holdings in Pfizer were worth $469,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Capital Advisory Group Advisory Services LLC increased its holdings in shares of Pfizer by 2.9% during the second quarter. Capital Advisory Group Advisory Services LLC now owns 13,542 shares of the biopharmaceutical company’s stock worth $328,000 after buying an additional 388 shares in the last quarter. Trust Co of the South increased its holdings in shares of Pfizer by 1.5% during the second quarter. Trust Co of the South now owns 29,386 shares of the biopharmaceutical company’s stock worth $712,000 after buying an additional 441 shares in the last quarter. Charter Oak Capital Management LLC increased its holdings in shares of Pfizer by 4.3% during the second quarter. Charter Oak Capital Management LLC now owns 10,663 shares of the biopharmaceutical company’s stock worth $258,000 after buying an additional 444 shares in the last quarter. Ballentine Partners LLC increased its holdings in shares of Pfizer by 0.5% during the second quarter. Ballentine Partners LLC now owns 93,228 shares of the biopharmaceutical company’s stock worth $2,260,000 after buying an additional 458 shares in the last quarter. Finally, Members Trust Co increased its stake in shares of Pfizer by 2.1% in the first quarter. Members Trust Co now owns 23,175 shares of the biopharmaceutical company’s stock valued at $587,000 after buying an additional 467 shares during the period. 68.36% of the stock is currently owned by institutional investors.

Pfizer Trading Down 1.8%

NYSE PFE opened at $25.22 on Friday. The business has a 50 day simple moving average of $24.83 and a 200 day simple moving average of $24.14. Pfizer Inc. has a one year low of $20.92 and a one year high of $30.08. The stock has a market capitalization of $143.39 billion, a P/E ratio of 13.41, a P/E/G ratio of 0.84 and a beta of 0.55. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The business had revenue of $14.65 billion during the quarter, compared to analysts’ expectations of $13.43 billion. During the same quarter last year, the firm posted $0.60 earnings per share. The firm’s revenue was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 7th will be paid a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 6.8%. Pfizer’s dividend payout ratio (DPR) is currently 91.49%.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on PFE shares. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Pfizer in a research note on Wednesday. UBS Group reaffirmed a “neutral” rating and issued a $28.00 price objective on shares of Pfizer in a research note on Wednesday, October 1st. Citigroup upped their price objective on Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a research note on Wednesday, August 6th. Wall Street Zen downgraded Pfizer from a “buy” rating to a “hold” rating in a research note on Sunday, September 28th. Finally, Morgan Stanley upped their price objective on Pfizer from $32.00 to $33.00 and gave the company an “equal weight” rating in a research note on Wednesday, August 6th. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus target price of $28.41.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.